Hemophilia
U & I Inc., USA
Payor Education Presentation
Last Updated;
January, 2012
Hemophilia
Facts
• Chronic genetic disorder characterized by a protein
deficiency that results in delayed blood clotting.
• Individuals with hemophilia typically have internal bleeds
affecting their joints and muscles.
• While hemophilia is the result of a mutation on the X
chromosome, approximately 33% of cases are random
mutations and not inherited.
• Since the mutation is located on the X chromosome,
males (having only one X) tend to be more symptomatic
than females.
• Hemophilia A is the deficiency of the Factor VIII protein.
• Hemophilia B is the deficiency of the Factor IX protein.
Hemophilia
By the Numbers
• There are roughly 20,000 hemophiliacs in the US,
nationwide.
• Hemophilia A accounts for about 80% of the cases while
Hemophilia B makes up the other 20%.
• Severe hemophilia accounts for roughly 50% of all cases in
the United States.
• Moderate and mild hemophilia each make up approximately
25% of the cases.
• The average medical cost for a person with hemophilia
(using all severities and both Hemophilia A & B) is
approximately $150,000.
• Clotting factor replacement products account for about 90%
of hemophiliac’s annual medical costs.
• The average cost for one dose of factor replacement is
Hemophilia
Treatment
• Treatments for hemophilia include intravenous clotting factor
replacement, icing the injury site, as well as compression and
elevation of the site.
• In order to avoid costly delays that cause a bleeding
episode to get worse and therefore require more factor and
time in order to recover, most individuals are trained to infuse
by themselves at home.
•Factor replacement therapy can take three forms; (which
form should be utilized is determined by the patient and their
doctor)
–Scheduled prophylaxis treatment is used to maintain a safe level of
clotting protein through intravenous infusions on a regular basis.
–Some people infuse prior to a more physical activity such as jogging
or biking to prevent bleeds at that time, however they do not infuse on
a regular schedule.
Hemophilia
Complications
• Many Complication can cause the costs of treating a person with hemophilia to
increase.
• here are several complications that are frequently seen with hemophilia
population.
• Co-morbidities such as HIV infection and Hepatitis can mean additional
medications and doctors visits and/or hospitalizations that drive up cost of care.
(Luckily HIV and Hepatitis have not been known to be transmitted through factor
use for many years, meaning that these really only impact the older generations
now.)
• Inhibitors result from the individual’s immune system rejecting the clotting factor
used in the replacement therapy. When this occurs, the cost of treatment and
factor usage can skyrocket.
–Roughly 33% of the people with severe hemophilia develop inhibitors.
–Immune tolerance therapy (also called Inhibitor Override Therapy) and bypass therapy
are the primary treatments for inhibitor patients.
–Once a person begins Override Therapy, compliance to the treatment regimen is
critical to success which means long term quality of life improvements as well as large
cost reductions.
• Joint damage is a large cause of long term problems and recurring bleeding
episodes. Treating a joint bleed correctly when they do occur can prevent or limit
Hemophilia
why u&i?
• at U & I, HEMOPHILIA IS OUR ONLY BUSINESS
• U & I’S UTILIZATION MANAGEMENT PROGRAM
SIGNIFICANTLY LOWERS HEMOPHILIA COSTS AND
IMPROVES QUALITY OF LIFE
• U & I UTILIZATION COST FOCUS: HEMOPHILIA SELF
CARE EDUCATION, BLEEDING PREVENTION, REDUCING
INFUSION, AND ASSAY MANAGEMENT
• U & I UTILIZATION MANAGEMENT PROCESS
– ASSESSMENT/MONITORING OF RISK WITH
MEASUREMENT OF TREATMENT/COMPLIANCE
– PRODUCTS/SERVICES/EDUCATION
–PERSONAL DELIVERY INTERVENTION
–CONTINUITY OF CARE WITH HTC/PAYOR
Hemophilia
Payor Education Presentation
U & I Inc., USA
5236 West Seneca St.
Vernon, NY 13476
info@unipartners.net
877 229 - 5248